Amylin, Takeda discontinue development of obesity drug

Cos. willing to investigate other obesity drugs

SAN DIEGO — Amylin Pharmaceuticals and Takeda Pharmaceutical have halted development of a treatment for obesity in mid-stage clinical trials, the two companies said.

The companies said the decision to discontinue development of a therapy that combines pramlintide and metreleptin was based on "a commercial reassessment of the pramlintide/metreleptin program … [that] took into account a revised development plan, as well as evolving dynamics within he obesity therapeutic area."

Nevertheless, the companies said they would continue investigating other treatments for obesity.

Recommended stories

Login or Register to post a comment.